KNBIF (Kane Biotech) Debt-to-Revenue : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kane Biotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Kane Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.92 Mil. Kane Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.47 Mil. Kane Biotech's annualized Revenue for the quarter that ended in Jun. 2026 was $0.02 Mil. Kane Biotech's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 was 58.81.

Kane Biotech Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Kane Biotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Debt-to-Revenue Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kane Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26 Jun26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

KNBIF vs VRTX, REGN, MRNA: Debt-to-Revenue Comparison

For the Biotechnology subindustry, Kane Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kane Biotech Debt-to-Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kane Biotech's Debt-to-Revenue falls into.


Kane Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Kane Biotech's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.96705745030093 + 0.71399890570855) / 0.30621377032955
=5.49

Kane Biotech's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.91823436123348 + 0.46543013215859) / 0.02352815249315
=58.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2026) Revenue data.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.